BY & LARGE PEPTIDES

SELECTIVE AMYLIN RECEPTOR AGONIST · INVESTIGATIONAL

Eloralintide 10mg



Eloralintide (LY3841136) · 10mg vial

RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY CONSUMPTION · NOT FOR SELF-ADMINISTRATION

Eloralintide is an investigational, long-acting peptide designed to selectively activate amylin receptors. Amylin is a pancreatic hormone co-secreted with insulin that is involved in satiety, gastric emptying and glucose regulation.

PRICING · PER VIAL

Mix & match any vials — 2–4 −10%, 5+ −15%

RETAIL 1 VIAL	2–4 −10%	5+ −15%
R1,400	R1,260	R1,190

HOW IT WORKS

Rather than acting on GLP-1 or GIP receptors, eloralintide targets the amylin pathway, which signals fullness and slows gastric emptying. Its extended half-life supports a once-weekly research schedule.

RESEARCH CONTEXT

A 48-week phase 2 trial published in The Lancet evaluated once-weekly doses from 1mg to 9mg in adults with obesity or overweight. It remains investigational and is not approved by any regulator.

VIAL CONTENTS & HANDLING

- 10mg eloralintide
- Single lyophilised vial

Quality & sourcing. Sourced from established manufacturers who test using HPLC analysis. COA available on request — **ask us on WhatsApp ↗**

Storage: keep unopened lyophilised vials in a cool, dark place. Once reconstituted, store in the fridge at 2–8°C and use within 2 months.

RESEARCH REFERENCE DOSAGE

10mg vial · 3ml water · 3.33mg/ml

LEVEL	AMOUNT	U100 UNITS	FREQUENCY
Beginner	1mg	**30 units**	1× weekly · any time
Intermediate	2.5mg	**75 units**	1× weekly · any time
Advanced	5mg	**150 units**	1× weekly · any time

Fixed 3ml · U100 device (1 unit = 0.01ml). Long-acting, once-weekly profile; titrate gradually. Advanced (150 units) exceeds one 100-unit syringe fill. Research reference only.

Dosing status: No approved dose. Trial dose levels describe study design and are not instructions for these vials.

REFERENCES

- The Lancet — Eloralintide, a selective amylin receptor agonist for obesity: 48-week phase 2 trial
- Lilly — Eloralintide phase 2 results (November 2025)